List of Daklinza drug patents

Daklinza is owned by Bristol-Myers Squibb.

Daklinza contains Daclatasvir Dihydrochloride.

Daklinza has a total of 5 drug patents out of which 0 drug patents have expired.

Daklinza was authorised for market use on 24 July, 2015.

Daklinza is available in tablet;oral dosage forms.

Daklinza can be used as method of inhibiting hepatitis c virus; method of inhibiting hepatitis c virus with daklinza and at least one additional compound having anti-hcv activity, method of inhibiting hepatitis c virus with daklinza and at least one additional compound having anti-hcv activity; method of inhibiting hepatitis c virus, method of inhibiting hepatitis c virus.

The generics of Daklinza are possible to be released after 13 June, 2031.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9421192 BRISTOL-MYERS SQUIBB Hepatitis C virus inhibitors
Aug, 2027

(4 years from now)

US8642025 BRISTOL-MYERS SQUIBB Hepatitis C virus inhibitors
Aug, 2027

(4 years from now)

US8329159 BRISTOL-MYERS SQUIBB Hepatitis C virus inhibitors
Jul, 2029

(6 years from now)

US8629171 BRISTOL-MYERS SQUIBB Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
Jun, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8900566 BRISTOL-MYERS SQUIBB Hepatitis C virus inhibitors
Aug, 2027

(4 years from now)

Drugs and Companies using DACLATASVIR DIHYDROCHLORIDE ingredient

Market Authorisation Date: 24 July, 2015

Treatment: Method of inhibiting hepatitis c virus with daklinza and at least one additional compound having anti-hcv activity; Method of inhibiting hepatitis c virus

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in